Antonio P Costa
Overview
Explore the profile of Antonio P Costa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bozal S, Sjogren G, Costa A, Brown J, Roberts S, Baker D, et al.
SLAS Discov
. 2024 Sep;
29(7):100182.
PMID: 39245180
The use of organoid models in biomedical research has grown substantially since their inception. As they gain popularity among scientists seeking more complex and biologically relevant systems, there is a...
2.
Duran T, Costa A, Kneski J, Xu X, Burgess D, Mohammadiarani H, et al.
Int J Pharm
. 2024 May;
659:124288.
PMID: 38815641
A method of producing liposomes has been previously developed using a continuous manufacturing technology that involves a co-axial turbulent jet in co-flow. In this study, coarse-grained molecular dynamics (CG-MD) simulations...
3.
OBrien Laramy M, Costa A, Cebrero Y, Joseph J, Sarode A, Zang N, et al.
Mol Pharm
. 2023 Jul;
20(8):4285-4296.
PMID: 37462906
The recent clinical and commercial success of lipid nanoparticles (LNPs) for nucleic acid delivery has incentivized the development of new technologies to manufacture LNPs. As new technologies emerge, researchers must...
4.
Yenduri G, Costa A, Xu X, Burgess D
Int J Pharm
. 2022 Mar;
619:121700.
PMID: 35358645
Liposomes were one of the earliest drug delivery vehicles used for anti-cancer therapeutics and similarly, lipid-based nanoparticles have been used for abundance of applications as gene therapies. The methods to...
5.
Gupta A, Costa A, Xu X, Burgess D
Int J Pharm
. 2021 Aug;
607:120946.
PMID: 34333023
A continuous polymeric micelle processing platform was successfully developed, which eliminated batch-to-batch variation in critical quality attributes (for example, size and polydispersity that are typically associated with batch processing). A...
6.
Gupta A, Costa A, Xu X, Lee S, Cruz C, Bao Q, et al.
Int J Pharm
. 2020 Apr;
583:119340.
PMID: 32305363
A continuous processing platform was developed to produce polymeric micelles. A block copolymer of mPEG (5kD)-PCL (2kD) was used as the model drug carrier. The polymeric micelles were produced using...
7.
Costa A, Xu X, Khan M, Burgess D
Pharm Res
. 2015 Oct;
33(2):404-16.
PMID: 26428671
Purpose: Liposomes are robust drug delivery systems that have been developed into FDA-approved drug products for several pharmaceutical indications. Direct control in producing liposomes of a particular particle size and...
8.
Costa A, Xu X, Burgess D
Pharm Res
. 2013 Jul;
31(1):97-103.
PMID: 23881305
Purpose: Freeze-thaw cycling is an important processing step in the preparation of liposomes that leads to the encapsulation of drug molecules. There is considerable variability in the number of freeze-thaw...
9.
Xu X, Costa A, Khan M, Burgess D
Int J Pharm
. 2012 Jun;
434(1-2):349-59.
PMID: 22683453
Quality by design (QbD) principles were explored in the current study to gain a comprehensive understanding of the preparation of superoxide dismutase (SOD) containing liposome formulations prepared using freeze-and-thaw unilamellar...
10.
Costa A, Xu X, Burgess D
Langmuir
. 2012 Jun;
28(26):10050-6.
PMID: 22671579
Higher than theoretical encapsulation efficiencies in liposomes of the cytoplasmic protein, superoxide dismutase (SOD), were previously observed. The high encapsulation of SOD led to the consideration of lipid-protein interactions and...